Trioxacarcin B  (Synonyms: TXN-B)

Trioxacarcin B (TXN-B) is a potent cytotoxic agent and DNA-targeted inhibitor. Trioxacarcin B disrupts DNA function and induces apoptosis in cancer cells. Trioxacarcin B not only effectively inhibits the growth of various Gram-positive and Gram-negative bacteria as well as Plasmodium falciparum, but also blocks the colony formation of cancer stem cells, significantly reduces tumor volume and prolongs survival in preclinical in vivo models. The activity of Trioxacarcin B is highly dependent on its intact spiro-epoxide structure; it loses efficacy once this moiety undergoes hydrolysis, and Trioxacarcin B shows no activity against fungi, microalgae and small RNA viruses. Trioxacarcin B can be used for research on bacterial infections, malaria, and various cancers including colon cancer and melanoma^[1][2][3].

Trioxacarcin B (30~40 μg; 9 mm 培养皿) 对 Bacillus subtilis、Escherichia coli、Staphylococcus aureus 和 Streptomyces viridochromogenes Tu 57 表现出体外抗菌活性；抑菌圈直径分别为 38 mm、32 mm、22 mm 和 27 mm^[2]。
Trioxacarcin B 对恶性疟原虫 (Plasmodium falciparum) K1 株和 NF54 株表现出体外抑制活性，24 h 处理后的平均 IC₅₀ 值分别为 102 ng/mL 和 82 ng/mL^[2]。
Trioxacarcin B 对一组永久性人类肿瘤细胞系表现出体外抗肿瘤活性，平均 IC₅₀ 为 1.107 μg/mL，平均 IC₇₀ 为 2.161 μg/mL，且在不同细胞系中的活性存在差异^[2]。
Trioxacarcin B 可在体外抑制 LXFL 529 大细胞肺癌异种移植肿瘤干细胞的集落形成，其 IC₅₀ 为 6.0 ng/mL，IC₇₀ 为 25.0 ng/mL，IC₉₀ 为 157.0 ng/mL^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

894.87

C₄₂H₅₄O₂₁

81534-36-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gruchot W. Trioxacarcin-based Antibody-Drug Conjugates: Optimization of payload structure and a triazene linker system design[D]. Harvard University, 2026.

  [2]. Maskey RP, et al. Anti-cancer and antibacterial trioxacarcins with high anti-malaria activity from a marine Streptomycete and their absolute stereochemistry. J Antibiot (Tokyo). 2004;57(12):771-779.  [Content Brief]